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Immune response to Brucella abortus strain RB51 vaccine was measured in cattle vaccinated at calfhood. After an increase at
day 6 post-vaccination (pv), the antibody level recorded in the 10 vaccinated animals remained constant for two months, and
then progressively decreased. All vaccinated animals remained negative from day 162pv to the end of the study (day 300pv).
Only at days 13 and 14pv the RB51-CFT showed 100% sensitivity (credibility interval (CI) 76.2%–100%). The results indicate
that the possibility to use RB51-CFT for the identiﬁcation of cattle vaccinated at calfhood with RB51 is limited in time. A
ﬁeld investigation was carried out on 26,975 sera collected on regional basis from the Italian cattle population. The study
outcomes indicate that in case of RB51-CFT positive results observed in oﬃcially Brucellosis-free (OBF) areas and, in any case,
when an illegal use of RB51 vaccine is suspected, the use of the RB51-CFT alone is not suﬃcient to identify all the vaccinated
animals. The design of a more sophisticated diagnostic protocol including an epidemiological investigation, the use of RB51-
CFT, and the use of the skin test with RB51 as antigen is deemed more appropriate for the identiﬁcation of RB51 vaccinated
animals.
Copyright © 2008 Manuela Tittarelli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The objective of brucellosis eradication was introduced in
the Italian legislation in year 1994 [1], thus forbidding the
vaccination of cattle against this disease. Brucella abortus
strain 19 vaccine, in smooth phase, induces the production
of antibodies that are detectable with the oﬃcial tests and
arenotdistinguishablefromthosefoundininfectedanimals.
A similar problem is present with the B. abortus strain
45/20 vaccine, even though this strain is in rough phase [2].
B.abortus strain RB51 vaccine (RB51), rough mutant of the
virulent strain B. abortus 2308, does not lead to the produc-
tionofantibodiesthatcanbedetectedusingtheconventional
serologicaltests[3,4].Giventhepossibilityofanillegaluseof
RB51, this characteristic may represent a serious interference
in the national eradication plan and may seriously harm the
achievement of oﬃcially Brucellosis-free (OBF) qualiﬁcation
for herds and territories, as well as the already gained
qualiﬁcations. Therefore, it has been considered necessary
to provide diagnostic tools able to guarantee an eﬀective
surveillance. Available literature reports the possibility to
detect speciﬁc RB51 antibodies with a complement ﬁxation
test (CFT) using RB51 as antigen ([RB51-CFT]; [5, 6]). Nev-
ertheless, the kinetics of the speciﬁc RB51 immune response
in cattle after calfhood vaccination, thus the probability
of identifying an illegal vaccination carried out on those
animals, have never been investigated. Moreover, the RB51-
CFT has never been evaluated on national cattle population.
Thus, the aims of the present study are to identify the
antibody kinetics of RB51-CFT in cattle vaccinated with
RB51 at calfhood, to evaluate the RB51-CFT on Italian
cattle population, and to carry out a preliminary study on
the possibility that RB51 vaccine has been used in this
population.2 Clinical and Developmental Immunology
2. MATERIALS AND METHODS
2.1. Vaccine
The RB51 vaccine was kindly provided by CZ Veterinaria
(Pontevedra, Spain), the European distributor of the prod-
uct,underlicensefromtheColoradoSerumCompany(Den-
ver, Colo, USA). Once reconstituted, the vaccine contained
5 ×109 CFU/mL of B. abortus strain RB51.
2.2. Animalsandvaccination
Fifteen Friesian calves, aged between four to six months
and obtained from OBF herds, were randomly selected
and divided into two groups. One group (n = 10) was
vaccinated subcutaneously with RB51 in accordance with
the instructions of the manufacturers (2mL reconstituted
solution, containing 10×109 colony-forming units (CFUs)).
The other group (n = 5 )w a su s e da sn o n v a c c i n a t e dc o n -
trol and the animals were inoculated subcutaneously with
2mL sterile saline solution. All the animals were stabled
with adequate space and fed with a standard diet (hay
and nutritional supplements) for the entire duration of the
experiment; all stages were conducted with consideration for
their welfare and all procedures with animals were carried
out in accordance to appropriate humane methods.
2.3. Serologicaltestingandantigens
A l la n i m a l sw e r et e s t e df o ra n t i - B. abortus and anti-RB51
antibodies before vaccination, on the day of vaccination (day
zero) and then periodically until Day 300 postvaccination
(pv). Anti-B. abortus antibodies were veriﬁed using the
Rose Bengal test (RBT) and CFT, both performed using the
B. abortus biovar 1 strain 99 as antigen (VLA Weybridge,
UK) and according to the methods described in the 5th
edition of the OIE Manual of Diagnostic Tests and Vaccines
for Terrestrial Animals [7]. Anti-RB51 antibodies were
monitored with an RB51 antigen-speciﬁc CFT (RB51-CFT).
The antigen was prepared from the same RB51 strain used
for vaccination, after growth in Brucella agar added with
5% bovine foetal serum. The antigen used in the RB51-CFT
was crosstitrated with a positive serum coming from a heifer
vaccinated with RB51, as described in literature [5, 6].
2.4. Fieldinvestigation
The ﬁeld investigation covered the 2001–2004 period and
was divided in two steps. For the 2001–2003 period, the
investigation was carried out on sera coming from the
National Serum Bank (NSB) placed in the Istituto Zooproﬁ-
lattico Sperimentale dell’Abruzzo e del Molise “G. Caporale”
(IZS A&M). The NSB collects and stores sera coming from
cattle used as sentinel in the framework of the National
Bluetongue Surveillance System (NBSS). Sentinels are bled
regularly with variable frequency, depending on the season
and bluetongue infection rate in the area concerned [8].
The herds to be tested were randomly selected from the
sentinel herds that were present in the 12 regions in which
the NBSS was in force during the period considered. Sera
Table 1: Number of sera from the National Serum Bank (NSB,
collected during the 2001–2003 period) and tested with RB51-CFT,
on regional basis.
Region of origin No. of sera tested No. of herds tested
Abruzzo 2,123 177
Apulia 1,836 207
Basilicata 1,957 222
Calabria 1,064 111
Campania 1,062 117
Liguria 2,552 193
Marche 2,825 238
Molise 2,584 217
Piedmont 2,489 139
Sardinia 1,282 110
Sicily 1,446 114
Umbria 1,196 103
Total 22,416 1,948
of all animals present in the sampled herds were tested with
RB51-CFT (22,416 sera analysed from 1,948 herds, Table 1).
For year 2004, sera collected by Local Veterinary Services in
the framework of the National Brucellosis Eradication Plan
(NBEP) were analysed by the local Istituti Zooproﬁlattici
Sperimentali (IZS), Italian National Veterinary Laboratories.
Sera were sampled according to a systematic sampling
method, with a sampling interval (intended as the number
of samples in between the sample selected and the next to
be selected) calculated for each region on the basis of the
number of samples tested for the NBEP in the year 2002.
The number of serum samples expected from each region
was set to 300, but not all the regions were able to reach the
objective. All sera were analysed with RB51-CFT (4,559 sera
analysed from 928 herds, Table 2). Moreover, NSB serum,
coming from Piedmont region (2,489 sera), NBEP sera from
Veneto region (300 sera), Friuli-Venezia Giulia region (185
sera), and the autonomous provinces of Trento and Bolzano
(300 sera), were used to calculate the threshold of RB51-CFT
(3,274 sera analysed in total).
2.5. Statisticalanalysis
In animals under experiment, and for each sampling day,
mean value, 25th percentile, 75th percentile, minimum value
and maximum value of titres resulting from the RB51-
CFT were recorded. Sensitivity and speciﬁcity values were
estimated and compared using a Bayesian approach [9].
Bayesian inference is an application of the Bayes theorem
[10] that allows the investigator to integrate any previous
knowledge (expressed as a prior probability distribution),
with the likelihood of obtaining a certain result if the
animal is infected or if the animal is healthy (likelihood
functions), with the results obtained by the application
of the tests to a given population (collected data). The
likelihood functions depend on the sensitivity and speciﬁcity
of the test(s) employed and on the uncertainty of their
values. The ﬁnal results are probability distribution of theManuela Tittarelli et al. 3
Table 2: Number of sera from the National Brucellosis Eradication
Program (NBEP, collected during year 2004) and tested with RB51-
CFT, on regional basis.
Region of origin No. of sera tested No. of herds tested
Apulia 302 61
Basilicata 300 59
Calabria 266 54
Campania 300 59
Emilia-Romagna 300 60
Friuli-Venezia Giulia 185 38
Liguria 251 55
Lombardy 300 60
Marche 315 79
Piedmont 300 61
Sardinia 300 62
Sicily 300 57
Trentino-Alto Adige 300 61
Umbria 240 46
Valle d’Aosta 300 56
Veneto 300 60
Total 4,559 928
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Figure 1: Median, maximum value, minimum value, 25th per-
centile, and 75th percentile of RB51-CFT results in vaccinated
animals (n = 10).
number of infected animals correctly identiﬁed as infected
(sensitivity) or of the number of healthy animals correctly
identiﬁed as healthy (speciﬁcity) in the sample or in the pop-
ulation (posterior probability). Probabilities of the various
possible sensitivity values were estimated using a binomial
likelihood function and an uninformed Uniform(0,1) prior
distribution. As existing knowledge on the sensitivity or
speciﬁcity of tests was considered to be virtually nil, an
uninformed Uniform(0,1) prior distribution was used. The
Uniform(0,1) distribution states that prior to the collection
of data, all true probability values are considered possible
within the range deﬁned for the number of true posi-
tives (sensitivity calculation) or true negatives (speciﬁcity
calculation). The RB51-CFT results were expressed as the
0
1
2
6
9
1
3
1
4
1
7
2
0
2
9
4
3
5
8
7
6
9
1
1
0
4
1
1
9
1
6
2
2
1
7
2
3
9
2
6
8
3
0
0
Days post vaccination
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
L
n
d
i
l
u
t
i
o
n
Figure 2: Median, maximum value, minimum value, 25th per-
centile, and 75th percentile of RB51-CFT results in control animals
(n = 5).
percentageofpositive animals ontested; theupperand lower
95% Credibility Intervals (CI) were calculated using a beta
probability distribution [11].
3. RESULTS
3.1. Serologicaltestingonexperimentally
vaccinatedanimals
Sera from all animals (RB51-vaccinated and controls) gave
negative results to RBT and CFT prior to vaccination, on
Day zero and during the entire study. All the animals were
also negative to RB51-CFT prior to vaccination and on
Day zero. After vaccination, vaccinated animals developed a
serological response to RB51-CFT. The results of RB51-CFT
on vaccinated animals and on controls are shown in Figures
1 and 2, respectively. Using the threshold resulted from
the ﬁeld investigation, the percentage of animals correctly
identiﬁed as vaccinated or unvaccinated by the RB51-CFT
are shown in Figures 3 and 4,r e s p e c t i v e l y .
3.2. Fieldinvestigation
The RB51-CFT threshold has been identiﬁed in the 100% of
ﬁxation at 1 : 4 serum dilution. This result corresponds to
the 90th percentile of the distribution of titres of all sera that
have shown reactivity in the RB51-CFT and to the 99.9th
percentile of the distribution of titres of sera coming from
Piedmont, Veneto and Fiuli-Venezia Giulia regions, and the
autonomous provinces of Trento and Bolzano. RB51-CFT
resultsonNSBsera(2001–2003period),expressedaccording
to the region of origin and as percent of animals resulted
positive on tested, are shown in Figure 5. RB51-CFT results
in NBEP sera (year 2004), expressed according to the region
of origin and animals resulted positive on tested, are shown
in Figure 6. Given that they have been used for the threshold
calculation,NSBserafromPiedmontregion,aswellasNBEP
sera from Veneto and Fiuli-Venezia Giulia regions and the
autonomous provinces of Trento and Bolzano, have not been
considered in Figures 5 and 6,r e s p e c t i v e l y .4 Clinical and Developmental Immunology
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Figure 3: Percent vaccinated animals correctly identiﬁed by the
RB51-CFT and 95% Credibility Intervals.
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Figure 4: Percent control animals correctly identiﬁed by the RB51-
CFT and 95% Credibility Intervals.
4. DISCUSSION
The results of the present study conﬁrm the possibility to
detect speciﬁc anti-RB51 antibodies with the RB51-CFT
[5, 6, 12]. Moreover, negative results to RBT and CFT
conﬁrm the impossibility to detect speciﬁc RB51 antibodies
with the conventional serological tests [3, 4], while the
use of Strains 19 or 45/20 would elicit the production of
antibodies detectable with conventional serological tests [2].
ThischaracteristicofRB51mightbeveryusefulforcountries
having a brucellosis control program based on vaccination.
Nonetheless, the choice of vaccines to be used should take
into consideration also other factors, namely:
(i) RB51 eﬃciency (compared with S19) and its innocu-
ousness remain controversial
(ii) ﬁeldexperienceindicatesthatitcaninduceabortionin
some cases if applied to pregnant cattle and that there
is excretion in milk in a relevant number of vaccinated
animals
(iii) RB51 could infect humans and it is highly resistant to
rifampicin, one of the antibiotics of choice for treating
human brucellosis. In addition, the diagnosis of the
infection produced by RB51 requires special tests not
available in most hospitals.
Allthesefactors,togetherwiththefrequencyofimmunosup-
pressed persons in the human population should be taken
into consideration in the choice of a vaccine to be used in
animal populations.
Beside the availability of tests with known performances,
to investigate on the possible illegal use of RB51 vaccine, it is
also necessary to know the antibody kinetics in cattle vacci-
nated at calfhood. After showing an increase at Day 6pv, the
antibody level recorded in the 10 vaccinated animals remains
practically constant for two months, and then progressively
decreases (Figure 1). In particular, considering the threshold
identiﬁed for the RB51-CFT with the ﬁeld investigation
carried out in the present study, only one animal is still
correctlyidentiﬁedoutofthe10experimentallyvaccinatedat
119dayspv(Figure 3).Allexperimentallyvaccinatedanimals
remain negative from Day 162pv to the end of the study (day
300pv). The RB51-CFT shows 100% sensitivity (CI 76.2%–
100%) only at days 13 and 14pv. Control animals show
resultstotheRB51-CFTalwaysinferiororequaltoareaction
of 100% ﬁxation at serum dilution 1 : 4 (Figure 2). Results
observed in experimentally vaccinated animals conﬁrm the
threshold identiﬁed with the ﬁeld investigation and show
that the possibility to use RB51-CFT for the identiﬁcation of
cattle vaccinated at calfhood with RB51 is limited in time.
The absence of positive results in the ﬁve control animals
gives an estimation of the speciﬁcity of 100%, with a CI
between 60.7% and 100% (Figure 4). Nevertheless, given
that this CI is somewhat wide, the RB51-CFT speciﬁcity is
better deﬁned when the results of the ﬁeld investigation are
considered (speciﬁcity 99.9%, CI 99.73%–99.96%). The ﬁeld
investigation reveals that in some Italian regions (namely,
Basilicata, Calabria, Campania, Liguria, Apulia, Sardinia,
Sicily, and Umbria) the number of positive results (Figure 5)
is higher than what would be expected on the basis of
the RB51-CFT speciﬁcity (as it has been standardized). As
a matter of fact, the expected percentage of false-positive
results to the RB51-CFT would be 0.1%, with a lower CI of
0.04%. Moreover, in the case of Liguria, Sicily, and Sardinia
regions, the lower CI of the percent positive animals is
higher than the upper CI of the percent positive animals
that would be expected on the basis of the test speciﬁcity.
Therefore, it is unlikely that the frequency of positive
results observed in these latter regions would be only due
to the eﬀect of case. The results shown in Figure 5 (sera
from the 2001–2003 period) are conﬁrmed for six regions
(namely, Basilicata, Calabria, Campania, Apulia, Sicily, and
Sardinia)bytheresultsobservedonsamplescollectedduring
2004 (Figure 6). These regions, in year 2004 also, show a
percentage of positive animals higher than expected on the
basis of test speciﬁcity. The positive results observed on
sera collected during the 2001–2003 period from Umbria
and Liguria regions (Figure 5)a r en o tc o n ﬁ r m e do ns e r a
collected in year 2004, where no positive result was recorded.
Moreover, for some regions (namely, Calabria, Campania,
Apulia, Sicily, and Sardinia) the lower CI of the percentage
of positive animals is higher than the percentage expected
on the basis of the upper CI of test speciﬁcity (Figure 6).
Although a possible illegal use of RB51 vaccine could be
explained for some of these regions (Calabria, Campania,Manuela Tittarelli et al. 5
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Figure 5: Percent of sera coming from the National Serum Bank
(NSB, collected during the 2001–2003 period) and resulted positive
to RB51-CFT, on regional basis.
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Figure 6: Percent of sera coming from the National Brucellosis
Eradication Plan (NBEP, collected during year 2004) and resulted
positive to RB51-CFT, on regional basis.
Apulia, Sicily) by the high brucellosis prevalence, by the
diﬃcultiesencounteredintheeradicationprocess,andbythe
frequentreinfectionsofcleanedherds(asdetectedduringthe
NBEP, Italian Ministry of Health, personal communication),
an illegal use of this vaccine remains diﬃcult to explain in
Sardinia region, which reached the status of OBF region in
April 2003 [13]. Nevertheless, Sardinia has intensive animal
trade with other Italian regions that in several occasions was
responsible of the reintroduction of Brucellosis in the island.
In the case of Sardinia, RB51-vaccinated animals could have
been imported from other Italian regions and this could
explain the presence of a positivity rate signiﬁcantly higher
than that expected on the basis of the test speciﬁcity.
Given the nature of the disease (vaccination cannot
avoid the infection of the animal and the related carrier
state), the passage from a brucellosis control program to a
brucellosis eradication program would necessarily imply to
forbid the use of any kind of vaccination. Once vaccination
is forbidden, an illegal use of RB51 in cattle can be expected
in areas with a relatively high prevalence because farmers
would try to decrease the number of abortions (and the
other economic losses associated with brucellosis, such as
the drop in fertility and/or in milk production) by using
a tool that cannot be identiﬁed by the Veterinary Services
with the routine brucellosis diagnostic procedures. Lacks in
the Oﬃcial Veterinary Services inspection activities, together
with the absence of an eﬀective surveillance system, are
conditions that encourage the illegal vaccination practices in
those areas. The uncontrolled spread of the vaccinal strain
would have eﬀects on the epidemiology of the ﬁeld strain
also, and this cannot be properly assessed (and therefore
controlled) without a reliable diagnostic tool to identify
animals vaccinated with RB51.
The results of the present study suggest that in case of
RB51-CFT-positive results observed in OBF areas (as the
ones observed in Sardinia region) and, in any case, when
an illegal use of RB51 vaccine is suspected, the use of the
RB51-CFT alone is not suﬃcient but it would be appropriate
to design a more sophisticated diagnostic protocol. The
use of a protocol which would include an epidemiological
investigation, the use of RB51-CFT, and the use of the skin
testwithRB51asantigen[12]couldgive important elements
to the ﬁnal correct interpretation of RB51-CFT results and
identiﬁcation of RB51-vaccinated animals.
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